Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, will announce its unaudited interim results for the six months ended 30 June 2021 on Thursday, 30 September 2021.
An investor webinar presentation by Alastair Smith, Chief Executive Officer and Tony Gardiner, Chief Financial Officer, will take place at 10:30am BST on Thursday, 30 September 2021.
The webinar is open to all existing and potential investors and will consist of a presentation followed by a Q&A session, held on the Investor Meet Company platform. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and then click “Add to meet” Avacta Group via the following link to join the webinar:
Investors who already follow Avacta Group plc on the Investor Meet Company platform will automatically be invited.